论文部分内容阅读
目的 观察中晚期肝癌肝动脉、门静脉双插管栓塞性化疗及在此基础上综合治疗的疗效及生存期。方法 38例肝癌患者随机分为A组 2 0例行肝动脉、门静脉碘油乳化化疗 ;B组 18例双插管碘油乳化化疗 +无水酒精注射 +免疫治疗。结果 A组接受治疗后 1、2、3年的生存期分别是 40 %、15 %、0 % ;B组为 72 %、44%、11% ,统计学上具有显著性意义 ,P <0 .0 5。B组多次化疗者占 83 % (15 /18) ,A组占 45 % (9/2 0 ) ,单次与多次化疗者 1、2、3年生存期分别是2 1%、7%、0 % ;75 %、42 %、8% ,P <0 .0 1。结论 以肝动脉、门静脉双插管碘油乳化化疗 +无水酒精注射 +免疫治疗取得最佳治疗效果和有效的延长生存期 ,是目前综合治疗中晚期肝癌的最佳治疗方法之一。
Objective To observe the efficacy and survival of dual embolization chemotherapy of hepatic artery and portal vein in advanced hepatocellular carcinoma on the basis of comprehensive treatment. Methods Thirty-eight patients with hepatocellular carcinoma were randomly divided into group A (20 cases) with hepatic artery and portal vein lipiodol emulsification chemotherapy and group B (18 cases) with double-cannula lipiodol emulsification chemotherapy + anhydrous alcohol injection + immunotherapy. Results The survival rates at 1, 2 and 3 years after treatment in group A were 40%, 15% and 0%, respectively; those in group B were 72%, 44% and 11%, respectively, with statistical significance (P <0). 0 5. Patients in group B received multiple chemotherapy for 83% (15 of 18 patients), patients in group A (45%) and patients with single and multiple doses of 1, 2 and 3 years of survival were 21% and 7% , 0%; 75%, 42%, 8%, P <0.01. Conclusions The best therapeutic effect and effective survival prolongation are achieved by hepatic artery and portal vein double intubation with lipiodol emulsion chemotherapy + anhydrous alcohol injection + immunotherapy. It is one of the best treatment methods for the comprehensive treatment of advanced liver cancer.